Free Trial
NASDAQ:RCEL

AVITA Medical (RCEL) Stock Price, News & Analysis

AVITA Medical logo
$9.23 +0.28 (+3.13%)
Closing price 04:00 PM Eastern
Extended Trading
$9.22 -0.01 (-0.11%)
As of 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About AVITA Medical Stock (NASDAQ:RCEL)

Key Stats

Today's Range
$8.66
$9.36
50-Day Range
$7.50
$10.57
52-Week Range
$6.90
$14.16
Volume
190,115 shs
Average Volume
180,760 shs
Market Capitalization
$241.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.25
Consensus Rating
Moderate Buy

Company Overview

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

Remove Ads

AVITA Medical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

RCEL MarketRank™: 

AVITA Medical scored higher than 29% of companies evaluated by MarketBeat, and ranked 819th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AVITA Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    AVITA Medical has only been the subject of 1 research reports in the past 90 days.

  • Read more about AVITA Medical's stock forecast and price target.
  • Earnings Growth

    Earnings for AVITA Medical are expected to grow in the coming year, from ($0.95) to ($0.04) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AVITA Medical is -3.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AVITA Medical is -3.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    AVITA Medical has a P/B Ratio of 54.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about AVITA Medical's valuation and earnings.
  • Percentage of Shares Shorted

    9.94% of the float of AVITA Medical has been sold short.
  • Short Interest Ratio / Days to Cover

    AVITA Medical has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in AVITA Medical has recently increased by 4.26%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    AVITA Medical does not currently pay a dividend.

  • Dividend Growth

    AVITA Medical does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.94% of the float of AVITA Medical has been sold short.
  • Short Interest Ratio / Days to Cover

    AVITA Medical has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in AVITA Medical has recently increased by 4.26%, indicating that investor sentiment is decreasing.
  • News Sentiment

    AVITA Medical has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for AVITA Medical this week, compared to 2 articles on an average week.
  • Search Interest

    Only 2 people have searched for RCEL on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added AVITA Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AVITA Medical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $111,150.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 1.82% of the stock of AVITA Medical is held by insiders.

  • Percentage Held by Institutions

    Only 27.66% of the stock of AVITA Medical is held by institutions.

  • Read more about AVITA Medical's insider trading history.
Receive RCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVITA Medical and its competitors with MarketBeat's FREE daily newsletter.

RCEL Stock News Headlines

AVITA Medical's (RCEL) "Buy" Rating Reiterated at D. Boral Capital
Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
See More Headlines

RCEL Stock Analysis - Frequently Asked Questions

AVITA Medical's stock was trading at $12.80 on January 1st, 2025. Since then, RCEL shares have decreased by 27.9% and is now trading at $9.23.
View the best growth stocks for 2025 here
.

AVITA Medical, Inc. (NASDAQ:RCEL) issued its earnings results on Thursday, February, 13th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.14. The firm earned $18.41 million during the quarter, compared to analysts' expectations of $18.40 million. AVITA Medical had a negative net margin of 96.26% and a negative trailing twelve-month return on equity of 337.91%.
Read the conference call transcript
.

AVITA Medical's top institutional investors include Rhumbline Advisers (0.15%) and GAMMA Investing LLC (0.02%). Insiders that own company stock include Michael S Perry, Robert Mcnamara, Donna Shiroma, Suzanne Crowe, Jeremy Curnock Cook and James Corbett.
View institutional ownership trends
.

Shares of RCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AVITA Medical investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD) and Tesla (TSLA).

Company Calendar

Last Earnings
2/13/2025
Today
4/15/2025
Next Earnings (Estimated)
5/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:RCEL
Fax
N/A
Employees
130
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$17.25
High Stock Price Target
$22.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+86.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-61,850,000.00
Pretax Margin
-96.17%

Debt

Sales & Book Value

Annual Sales
$64.25 million
Price / Cash Flow
N/A
Book Value
$0.17 per share
Price / Book
54.29

Miscellaneous

Free Float
25,741,000
Market Cap
$241.99 million
Optionable
Optionable
Beta
1.60

Social Links

10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:RCEL) was last updated on 4/15/2025 by MarketBeat.com Staff
From Our Partners